A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

NCT04574869 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Low probability of enrolling patients prior to expiry of study drug.

Conditions

Acute Lung Injury
ALI
COVID-19

Interventions

DRUG: RLS-0071 10 mg/kg
DRUG: RLS-0071 40 mg/kg
DRUG: Placebo
DRUG: RLS-0071 10 mg/kg
DRUG: RLS-0071 40 mg/kg

Sponsor

ReAlta Life Sciences, Inc.